Recursion Pharmaceuticals, Inc. RXRX
Weak (early) Emerging Frontier sector · Recursion — AI-driven drug-discovery platform, pre-profit biotech.
🗓 Reports earnings in 74 days (2026-11-04) — calendar context, not a prediction.
Recursion Pharmaceuticals, Inc. (RXRX) is an early-stage Emerging Frontier company, graded Weak (early) on FrontierLab's evidence-based quality rubric (data as of 2026-08-21). Revenue grew -14.9% year-over-year at a -46.7% gross margin. Gross-profits-to-assets is -0.02; Rule of 40 is -1006.6. Net share issuance 27.6% YoY (heavy issuance). 4 risk flags are noted below. Analyst mix: 8 buy / 5 hold / 0 sell.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | -14.9% |
|---|---|
| Gross margin | -46.7% |
| Gross profits / assets | -0.02 |
| Rule of 40 | -1006.6 |
| Net margin | -991.7% |
| Cash runway (months) | 18.7 |
| PEG | — |
| Price / sales | 31.9 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ✗ Revenue growth — -14.9% (pass ≥ 20%)
- ✗ Capital efficiency
- ✗ Gross margin — -46.7% (pass ≥ 45% · Emerging Frontier)
- ✗ Gross-margin trend — -42.9 (pass ≥ 2)
- ✗ Share dilution — 27.6%
- ✗ Competitive moat — None
- ✓ Market size (TAM) — Large
Grade history
- 2026-08-07 — Weak (early) (from Insufficient)
- 2026-08-03 — Insufficient (from Weak (early))
- 2026-06-10 — Weak (early) (first graded)
Every grade change since FrontierLab began tracking this name — the receipts behind the current grade.
How have Early-stage-graded names performed?
The forward returns of all Early-stage-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 69% of Early-stage-graded names beat the S&P over 21 sessions (95% CI 51–82%, N=32). | Median excess vs the S&P was +3.9%. |
| ~3 months | building — 13 more sessions needed | |
| ~6 months | building — 76 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| Burning cash — operating margin is negative. | 35 | +7.4% |
| Thin gross margin — keeps little of each sales dollar (judge it against its industry). | 20 | +2.1% |
| Heavy dilution (~28%/yr) — top-decile share issuers have historically underperformed. | sample still too small to report (need ≥ 8) | |
| Parabolic one-day spike (+13%) in the last month — extreme single-day moves tend to mean-revert. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
How it compares
Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.
Fundamentals
| Market cap | $1.75B |
|---|---|
| Stage | Early |
| Share issuance (YoY) | 27.6% · heavy issuance |
| Moat | None |
| TAM | LARGE |
| P/E (trailing) | — |
| EPS (trailing) | $-1.04 |
| Burn multiple | 6.4 |
| Gross-margin trend (pts) | -42.9 |
| Cash / assets | 0.45 |
| Accruals (%) | -13.4% |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-05 |
Momentum context — describes the past, not a signal
Low reached Mar 30, 2026 · high reached Oct 15, 2025 — by daily close.
| Price | $3.34 (as of 2026-08-20) |
|---|---|
| Last session move | — |
| % off 52-wk high | -53.5% |
| RSI (14) | 54 |
| Relative volume | 1.3× |
Risk flags
Insider activity (90 days)
| Cluster buyers | 0 |
|---|---|
| Sellers | 4 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 2 |
|---|---|
| Buy | 6 |
| Hold | 5 |
| Sell | 0 |
| Strong sell | 0 |
• Coverage changed — coverage 14→13 analysts over ~5 weeks (per aggregated analyst ratings)
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
AI take — daily, AI-generated
AI leans cautious
Negative growth (-14.9%), deeply negative margins (-46.7%), and losses make this a value trap despite retail optimism.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Emerging Frontier names
← All Emerging Frontier names · Open RXRX in the interactive screener →
Data as of 2026-08-21 08:12 (end-of-day). How grades are computed →